Cargando…

Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study

BACKGROUND: In Colombia, all paid workers earning minimum wage or higher contribute part of their salary for access to the national health-care system through a type of insurance called contributive plan, which supports the remaining low-income population that is enrolled on the subsidised plan. Dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Ospina-Serrano, Aylen Vanessa, Bruges, Ricardo, Ramos, Pedro, Bernal, Laura, Aruachan, Sandra, Quiroga, Alicia, Rivas, Giovanna, Munévar, Isabel, Mantilla, William, Sánchez-Vanegas, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278887/
http://dx.doi.org/10.1016/S1470-2045(22)00438-7
_version_ 1784746280657879040
author Ospina-Serrano, Aylen Vanessa
Bruges, Ricardo
Ramos, Pedro
Bernal, Laura
Aruachan, Sandra
Quiroga, Alicia
Rivas, Giovanna
Munévar, Isabel
Mantilla, William
Sánchez-Vanegas, Guillermo
author_facet Ospina-Serrano, Aylen Vanessa
Bruges, Ricardo
Ramos, Pedro
Bernal, Laura
Aruachan, Sandra
Quiroga, Alicia
Rivas, Giovanna
Munévar, Isabel
Mantilla, William
Sánchez-Vanegas, Guillermo
author_sort Ospina-Serrano, Aylen Vanessa
collection PubMed
description BACKGROUND: In Colombia, all paid workers earning minimum wage or higher contribute part of their salary for access to the national health-care system through a type of insurance called contributive plan, which supports the remaining low-income population that is enrolled on the subsidised plan. During the COVID-19 pandemic, Colombia documented high mortality rate in patients with cancer, with higher mortality among low-income patients, according to data from our national registry of COVID-19 infection in patients with cancer. The aim of this research was to establish the differential access to COVID-19 vaccination depending on health insurance type, and its impact on mortality due to COVID-19 infection. METHODS: A cohort study was conducted with data from the Colombian National Cancer and COVID-19 Registry. Data were collected between June 1, 2021, when COVID-19 vaccines became available for patients with cancer in Colombia, and Oct 31, 2021. Included patients were aged 18 years or older, had a diagnosis of a solid tumour, were receiving active treatment or on follow-up, and had a confirmed SARS-CoV-2 infection. The cumulative incidence of mortality in the vaccinated and unvaccinated cohorts was compared. The estimation of the effect was done through relative risk (RR), and a multivariate analysis (generalised linear model, binomial family) was then done to estimate the effect of the type of health insurance. FINDINGS: 896 patients were included. 470 (52%) were older than 60 years; 530 (59%) were women and 366 (41%) were men. 172 (19%) patients were vaccinated and 724 (81%) patients were not vaccinated (resulting in a ratio of 1:4). According to the type of health insurance, the vaccine was administered to 26 (12%) of 211 patients in the subsidised plan and to 146 (21%) of 685 patients in the contributive plan. The rate of vaccination according with socioeconomic status was 69 (16%) of 430 patients in the low-income group, 75 (23%) of 329 in middle-income group, and 12 (29%) of 42 in high-income group. The cumulative incidence of mortality for all causes was 17% (n=123) in the non-vaccinated cohort and 5% (n=8) in vaccinated cohort. The cumulative incidence of mortality per health-care insurance was 24% (n=50) in the subsidised plan and 12% (n=81) in the contributive plan. The adjusted RR for mortality was 3·4 (95% CI 1·7–6·8) in unvaccinated versus vaccinated patients, and 1·8 (1·3–2·4) in patients on the subsidised versus the contributive plan. INTERPRETATION: Patients on the subsidised health plan in Colombia had higher mortality due to COVID-19 infection and less access to vaccines than patients with a contributive plan. Strategies to promote COVID-19 vaccination for all patients with cancer should be strengthened, with implementation of special measures to improve care for the low-income population. FUNDING: None.
format Online
Article
Text
id pubmed-9278887
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-92788872022-07-14 Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study Ospina-Serrano, Aylen Vanessa Bruges, Ricardo Ramos, Pedro Bernal, Laura Aruachan, Sandra Quiroga, Alicia Rivas, Giovanna Munévar, Isabel Mantilla, William Sánchez-Vanegas, Guillermo Lancet Oncol Abstracts BACKGROUND: In Colombia, all paid workers earning minimum wage or higher contribute part of their salary for access to the national health-care system through a type of insurance called contributive plan, which supports the remaining low-income population that is enrolled on the subsidised plan. During the COVID-19 pandemic, Colombia documented high mortality rate in patients with cancer, with higher mortality among low-income patients, according to data from our national registry of COVID-19 infection in patients with cancer. The aim of this research was to establish the differential access to COVID-19 vaccination depending on health insurance type, and its impact on mortality due to COVID-19 infection. METHODS: A cohort study was conducted with data from the Colombian National Cancer and COVID-19 Registry. Data were collected between June 1, 2021, when COVID-19 vaccines became available for patients with cancer in Colombia, and Oct 31, 2021. Included patients were aged 18 years or older, had a diagnosis of a solid tumour, were receiving active treatment or on follow-up, and had a confirmed SARS-CoV-2 infection. The cumulative incidence of mortality in the vaccinated and unvaccinated cohorts was compared. The estimation of the effect was done through relative risk (RR), and a multivariate analysis (generalised linear model, binomial family) was then done to estimate the effect of the type of health insurance. FINDINGS: 896 patients were included. 470 (52%) were older than 60 years; 530 (59%) were women and 366 (41%) were men. 172 (19%) patients were vaccinated and 724 (81%) patients were not vaccinated (resulting in a ratio of 1:4). According to the type of health insurance, the vaccine was administered to 26 (12%) of 211 patients in the subsidised plan and to 146 (21%) of 685 patients in the contributive plan. The rate of vaccination according with socioeconomic status was 69 (16%) of 430 patients in the low-income group, 75 (23%) of 329 in middle-income group, and 12 (29%) of 42 in high-income group. The cumulative incidence of mortality for all causes was 17% (n=123) in the non-vaccinated cohort and 5% (n=8) in vaccinated cohort. The cumulative incidence of mortality per health-care insurance was 24% (n=50) in the subsidised plan and 12% (n=81) in the contributive plan. The adjusted RR for mortality was 3·4 (95% CI 1·7–6·8) in unvaccinated versus vaccinated patients, and 1·8 (1·3–2·4) in patients on the subsidised versus the contributive plan. INTERPRETATION: Patients on the subsidised health plan in Colombia had higher mortality due to COVID-19 infection and less access to vaccines than patients with a contributive plan. Strategies to promote COVID-19 vaccination for all patients with cancer should be strengthened, with implementation of special measures to improve care for the low-income population. FUNDING: None. Elsevier Ltd. 2022-07 2022-07-13 /pmc/articles/PMC9278887/ http://dx.doi.org/10.1016/S1470-2045(22)00438-7 Text en Copyright © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Abstracts
Ospina-Serrano, Aylen Vanessa
Bruges, Ricardo
Ramos, Pedro
Bernal, Laura
Aruachan, Sandra
Quiroga, Alicia
Rivas, Giovanna
Munévar, Isabel
Mantilla, William
Sánchez-Vanegas, Guillermo
Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study
title Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study
title_full Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study
title_fullStr Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study
title_full_unstemmed Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study
title_short Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study
title_sort impact of health insurance type on access to vaccination and mortality due to covid-19 on patients with cancer in colombia: a cohort study
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278887/
http://dx.doi.org/10.1016/S1470-2045(22)00438-7
work_keys_str_mv AT ospinaserranoaylenvanessa impactofhealthinsurancetypeonaccesstovaccinationandmortalityduetocovid19onpatientswithcancerincolombiaacohortstudy
AT brugesricardo impactofhealthinsurancetypeonaccesstovaccinationandmortalityduetocovid19onpatientswithcancerincolombiaacohortstudy
AT ramospedro impactofhealthinsurancetypeonaccesstovaccinationandmortalityduetocovid19onpatientswithcancerincolombiaacohortstudy
AT bernallaura impactofhealthinsurancetypeonaccesstovaccinationandmortalityduetocovid19onpatientswithcancerincolombiaacohortstudy
AT aruachansandra impactofhealthinsurancetypeonaccesstovaccinationandmortalityduetocovid19onpatientswithcancerincolombiaacohortstudy
AT quirogaalicia impactofhealthinsurancetypeonaccesstovaccinationandmortalityduetocovid19onpatientswithcancerincolombiaacohortstudy
AT rivasgiovanna impactofhealthinsurancetypeonaccesstovaccinationandmortalityduetocovid19onpatientswithcancerincolombiaacohortstudy
AT munevarisabel impactofhealthinsurancetypeonaccesstovaccinationandmortalityduetocovid19onpatientswithcancerincolombiaacohortstudy
AT mantillawilliam impactofhealthinsurancetypeonaccesstovaccinationandmortalityduetocovid19onpatientswithcancerincolombiaacohortstudy
AT sanchezvanegasguillermo impactofhealthinsurancetypeonaccesstovaccinationandmortalityduetocovid19onpatientswithcancerincolombiaacohortstudy